41 filings
8-K
ALVR
AlloVir Inc
12 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:34pm
8-K
ALVR
AlloVir Inc
4 Jan 24
Cost Associated with Exit or Disposal Activities
5:21pm
8-K
ALVR
AlloVir Inc
22 Dec 23
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, anĀ AllogeneicĀ Virus-Specific T Cell Therapy
7:07am
8-K
ALVR
AlloVir Inc
2 Nov 23
AlloVir Reports Third Quarter 2023 Financial Results
8:11am
8-K
ALVR
AlloVir Inc
3 Aug 23
AlloVir Reports Second Quarter 2023 Financial Results
7:34am
8-K
sfji1ncyj43hbjydbjau
26 Jun 23
AlloVir Announces Proposed Public Offering of Common Stock
4:14pm
8-K
d3mbx1v
21 Jun 23
Other Events
4:09pm
8-K
w9qx6y qu06w
16 May 23
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
5l1y2hd9qnhtlbc6
4 May 23
AlloVir Reports First Quarter 2023 Financial Results
7:09am
8-K
ylqcke6d2
23 Feb 23
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
4:31pm
8-K
5s2m29b5l 5k
15 Feb 23
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
8:05am
8-K
ch4yjc9m3gjjm7epuq5
9 Jan 23
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
7:07am
8-K
ziy t4i86
21 Nov 22
Departure of Directors or Certain Officers
4:07pm
8-K
5fp0e9lk
3 Nov 22
AlloVir Reports Third Quarter 2022 Financial Results
7:28am
8-K
8cqgldgxmx8ljvcgj24
4 Aug 22
AlloVir Reports Second Quarter 2022 Financial Results
7:48am
8-K
ucdw1 4fj37k4u3ez
27 Jul 22
AlloVir Announces $126.6 Million Registered Direct Offering
8:22am
8-K
1lsvx
19 May 22
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
2ptxrsa9ifx
5 May 22
AlloVir Reports First Quarter 2022 Financial Results
7:36am
8-K
593 m10gcamkbkav
31 Mar 22
AlloVir Appoints Shawn Tomasello to Its Board of Directors
7:12am
8-K
8jhgw8d dm1
10 Feb 22
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
7:33am